Polypharmacy

Clinical Approach to Polypharmacy in Older Adults

Topic Overview

Polypharmacy is defined as the concurrent use of multiple medications—most commonly five or more—by a single patient. In adult and geriatric populations, polypharmacy is associated with increased risks of adverse drug events (ADEs), drug-drug interactions, medication nonadherence, functional decline, hospitalizations, and mortality.[1] For the Family Nurse Practitioner (FNP) exam, polypharmacy is a high-yield topic because it crosses multiple clinical domains: pharmacology, geriatrics, chronic disease management, and patient safety. Mastery of screening tools such as the Beers Criteria and STOPP/START criteria is essential for safe prescribing and deprescribing.[2]

Key Concepts and Definitions

  • Polypharmacy – Use of 5 or more medications concurrently. Hyperpolypharmacy is ≥10 medications.[1]
  • Potentially Inappropriate Medication (PIM) – A drug whose risks outweigh benefits in older adults, especially when safer alternatives exist. The Beers Criteria list PIMs.[2]
  • Deprescribing – The systematic process of tapering or stopping medications to reduce polypharmacy and improve outcomes.[3]
  • Medication Reconciliation – The process of comparing a patient’s current medication list against new orders to identify discrepancies and prevent errors.[4]
  • Prescribing Cascade – When an ADE is misinterpreted as a new medical condition, leading to the addition of a new drug to treat the side effect, further increasing polypharmacy.[5]

Core Principles and Processes

Why Polypharmacy Develops

  • Multiple comorbidities – Each condition may require one or more guideline-recommended therapies.
  • Multiple prescribers – Lack of coordinated care can lead to duplication and interaction.
  • Age-related pharmacokinetic changes – Reduced renal/hepatic clearance, increased drug half-life, higher risk of toxicity.[6]
  • Self-medication with OTC or herbal products – Often not disclosed to clinicians.

Stepwise Clinical Approach for the FNP

  1. Comprehensive Medication Review (Brown Bag Method) – Ask the patient to bring all prescription, OTC, and herbal products to every visit.[4]
  2. Identify High-Risk Medications – Using tools like the 2019 AGS Beers Criteria and STOPP/START criteria.[2]
  3. Assess Appropriateness – Evaluate each drug’s indication, dose, duration, and potential for harm.
  4. Prioritize Deprescribing – Target drugs with highest risk/benefit imbalance. Use validated deprescribing algorithms (e.g., for proton pump inhibitors, benzodiazepines, anticholinergics).[3]
  5. Monitor and Follow-Up – After deprescribing, assess for withdrawal effects, recurrence of symptoms, and need for nonpharmacologic alternatives.

Signs, Symptoms, and Clinical Features

Polypharmacy-related adverse effects can mimic geriatric syndromes. Be alert for the following when evaluating an older adult:

  • Falls and gait instability – Often linked to sedatives, antihypertensives, or hypoglycemics.
  • Delirium or cognitive decline – Anticholinergic burden from medications like diphenhydramine, oxybutynin, or tricyclic antidepressants.[2]
  • Orthostatic hypotension – Common with alpha-blockers, diuretics, and antidepressants.
  • Electrolyte disturbances – Hyponatremia from SSRIs or thiazides; hyperkalemia from ACE inhibitors or spironolactone.
  • Gastrointestinal bleeding or ulcer – NSAIDs, anticoagulants, antiplatelets.
  • Malaise, fatigue, anorexia – Nonspecific but often drug-related.

Assessment, Diagnosis, and Evaluation

  • Use the Beers Criteria (2019 Update) – A comprehensive list of PIMs organized by drug class. High-yield for exam: benzodiazepines, skeletal muscle relaxants, anticholinergics, and PPIs (for >8 weeks) are all PIMs.[2]
  • STOPP/START Criteria – Screening Tool of Older Persons’ Prescriptions (STOPP) identifies potentially inappropriate medications; Screening Tool to Alert doctors to Right Treatment (START) identifies prescribing omissions.[7]
  • Medication Appropriateness Index (MAI) – A validated tool to quantify the appropriateness of each medication based on indication, effectiveness, dose, direction, practicalities, and duplication.
  • Laboratory monitoring – Renal function (eGFR), hepatic function, electrolytes, drug levels (e.g., digoxin, warfarin).

Treatment, Interventions, and Patient Care

Deprescribing Strategies

  • Use a shared decision-making model – Discuss goals of care, potential risks/benefits, and patient preferences.
  • Taper slowly – Especially for benzodiazepines, opioids, and SSRIs to avoid withdrawal syndromes.
  • Replace with nonpharmacologic interventions – Physical therapy for pain/frailty, cognitive behavioral therapy for insomnia, dietary modifications for GERD.
  • Communicate with all prescribers – Provide a clear list of changes and rationale.

Common High-Yield Deprescribing Targets

  • Proton Pump Inhibitors (PPIs) – Taper or discontinue if no clear indication (e.g., not for GI prophylaxis in low-risk patients). Use H2RA or antacids if needed.[3]
  • Benzodiazepines – Taper by 25% every 1–2 weeks; consider CBT and sleep hygiene.
  • Anticholinergics – Strongly PIM; switch to non-anticholinergic alternatives (e.g., darifenacin over oxybutynin).
  • NSAIDs – Avoid long-term use in older adults; use acetaminophen or topical agents.

Patient Education

  • Encourage a single pharmacy and a medication list wallet card.
  • Teach patients to report new symptoms (e.g., dizziness, confusion) as potential drug effects.
  • Emphasize that fewer medications can sometimes improve quality of life and reduce falls.

Safety Precautions and Complications

  • Withdrawal syndromes – Abrupt cessation of beta-blockers, opioids, benzodiazepines, or antidepressants can be dangerous. Always taper.[3]
  • Drug-drug interactions – Use reliable interaction checkers; common high-yield: warfarin + NSAIDs, ACE inhibitors + potassium, digoxin + amiodarone.
  • Renal impairment – Dose adjustment required for many drugs; monitor eGFR and creatinine clearance.
  • Fall risk – Reduce or stop centrally acting agents when possible. Use the STOPPFall tool to identify fall-risk-inducing drugs.[8]
  • Prescribing cascade – Be alert; do not add a new drug to treat a side effect without first considering deprescribing the offending agent.

Exam Tips and High-Yield Points

  • Memorize the top PIMs from the Beers Criteria – Anticholinergics, benzodiazepines, nonbenzodiazepine hypnotics (z-drugs), PPIs (for >8 weeks), sulfonylureas with long half-life (glibenclamide), NSAIDs.
  • Number of medications is the strongest predictor of ADEs – Risk increases exponentially beyond 5–9 drugs.
  • Know the tools – Beers Criteria (American Geriatrics Society), STOPP/START (Irish/European). The Beers Criteria is the most frequently tested on FNP exams.
  • Deprescribing is an active skill – Steps: review, identify, prioritize, taper, monitor.
  • Common exam scenario – An 82-year-old on 10 medications for hypertension, diabetes, insomnia, and osteoarthritis presents with falls and confusion. Answer: review for anticholinergic burden (e.g., amitriptyline for neuropathy) and benzodiazepines; deprescribe.
  • Memory aid: “START with STOPP” – START highlights omissions (e.g., missing osteoporosis therapy), STOPP highlights inappropriate medications.

References & Sources

  1. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics. 2017;17(1):230. https://doi.org/10.1186/s12877-017-0621-2
  2. American Geriatrics Society 2023 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71(7):2052-2081. https://doi.org/10.1111/jgs.18372
  3. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827-834. https://doi.org/10.1001/jamainternmed.2015.0324
  4. Rochon PA, Gurwitz JH. The prescribing cascade: a medication management model for older adults. J Am Geriatr Soc. 2017;65(11):2339-2343. https://doi.org/10.1111/jgs.15052
  5. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6-14. https://doi.org/10.1046/j.1365-2125.2003.02007.x
  6. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213-218. https://doi.org/10.1093/ageing/afu145
  7. van der Velde N, Seppala LJ, Hartikainen S, et al. European Academy of Clinical Pharmacology: STOPPFall (Screening Tool of Older Persons Prescriptions for Fall Risk). Br J Clin Pharmacol. 2021;87(4):1678-1690. https://doi.org/10.1111/bcp.14568

Ready to test your knowledge?

Master the core responsibilities, scope of practice, and limitations for the Family Nurse Practitioner exam.

Start Practice Questions
Previous Topic Next Topic